Cardiac surgeon Yuriy Dudiy, MD, implanted the device in a 63-year-old male diagnosed with advanced heart failure on July 18.
Impella BTR received FDA investigational device exemption in December 2021. It is a percutaneous forward-flow heart pump capable of greater than 6 liters of blood flow per minute. Less invasive than current left ventricular assist devices, it can be implanted through a small incision in the chest.
The device, developed by medical technology company Abiomed, is designed to provide patients with chronic heart failure a longer-term, minimally invasive heart pump option.
Hackensack medical center is one of five hospitals in the U.S. selected to participate in the FDA-approved clinical trial.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
